Developability of New Monoclonal Antibody-based Immunotherapeutics for Cancer

Abstract

Therapeutic monoclonal antibodies (mAbs) have become the top-selling drugs mainly due to their unmatched target specificity and efficacy in treating a variety of diseases, including different types of cancer. Various relatively new formats of antibody-based products include antibody-drug-conjugates (ADCs), bispecifics and antibody-nanoparticle complexes. These modalities exploit target specificity of antibodies while providing additional benefits.
Formulation of mAbs is difficult due to instabilities such as protein aggregation. Potential side effects of protein aggregates include immunogenicity and other adverse effects; hence, developability of a product is of utmost importance from the get-go. Even though numerous predictive tools exist, most processing steps of mAb development still rely on costly and time-consuming trial-and-error methods.

This talk will provide a summary of the current state-of-play of the development of mAbs as well as other antibody-based therapies and provide new advancements mainly from our own lab. These include ADCs, bispecifics, and nanoparticle-mAb complexes. New strategies to enhance formulation stability will also be mentioned.